Literature DB >> 15517899

Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer.

Ian F Faneyte1, Petra M P Kristel, Marc J van de Vijver.   

Abstract

BACKGROUND: Multidrug resistance associated proteins MRP1, MRP2 and MRP3 confer in vitro multidrug resistance. We investigated their role in breast cancer resistance to anthracycline-based chemotherapy.
MATERIALS AND METHODS: Using real-time reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC), the expression of MRP1 - 3 was quantified in nine breast cancer cell lines and 30 breast carcinoma samples.
RESULTS: MRP1 - 3 mRNA was detectable in all breast cancer cell lines and tumor samples. No increase of expression was detected between untreated carcinoma and post-neoadjuvant anthracycline treatment tumor samples. IHC failed to detect the proteins. MRP1 - 3 expression was not associated with tumor response to treatment or with outcome.
CONCLUSION: MRP1 - 3 are expressed in breast cancer cells, but are not detected with IHC. We have found no evidence linking these proteins to clinical drug resistance in a small but well-documented series of breast cancer samples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517899

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance.

Authors:  João Conde; Nuria Oliva; Natalie Artzi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

2.  Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.

Authors:  Marie Ehrlichova; Radka Vaclavikova; Iwao Ojima; Antonella Pepe; Larisa V Kuznetsova; Jin Chen; Jaroslav Truksa; Jan Kovar; Ivan Gut
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-30       Impact factor: 3.000

3.  Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).

Authors:  Jing Zhang; Ka-Yun Ng; Paul C Ho
Journal:  AAPS J       Date:  2010-04-20       Impact factor: 4.009

Review 4.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

5.  Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide.

Authors:  J Damrot; T Nübel; B Epe; W P Roos; B Kaina; G Fritz
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

Review 6.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

7.  Glutathione participates in the modulation of starvation-induced autophagy in carcinoma cells.

Authors:  Enrico Desideri; Giuseppe Filomeni; Maria Rosa Ciriolo
Journal:  Autophagy       Date:  2012-09-10       Impact factor: 16.016

8.  Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.

Authors:  Nancy Egerton
Journal:  P T       Date:  2008-09

9.  Association between polymorphisms of XRCC1, p53 and MDR1 genes, the expression of their protein products and prognostic significance in human breast cancer.

Authors:  Silvia Rybárová; Janka Vecanová; Ingrid Hodorová; Jozef Mihalik; Martina Čižmáriková; Ján Mojžiš; Peter Solár; Marián Benický; Marian Adamkov; Ladislav Mirossay
Journal:  Med Sci Monit       Date:  2011-12

10.  MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells.

Authors:  Mario Martínez Soldevilla; Helena Villanueva; Noelia Casares; Juan Jose Lasarte; Maurizio Bendandi; Susana Inoges; Ascensión López-Díaz de Cerio; Fernando Pastor
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.